<DOC>
	<DOC>NCT00151931</DOC>
	<brief_summary>The purpose of this study is to assess phosphate reduction and control in patients with End Stage Renal Disease treated with lanthanum carbonate</brief_summary>
	<brief_title>Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Males and females of childbearing potential agree to take adequate precautions to prevent contraception Patients diagnosed with ESRD must have been receiving a stable dialysis regimen for chronic renal failure for the 2 consecutive months prior to enrollment in the study Patient requires treatment for hyperphosphataemia Pregnant or lactating women Patients who continue to require treatment with compounds containing calcium, aluminum or magnesium Patients with clinically significant uncontrolled concurrent illness, a lifethreatening malignancy or current multiple myeloma Patients who are HIV+ Patients with any significant gastrointestinal surgery or disorders</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>